BMC Infectious Diseases

Table 3 Antifungal susceptibilities of 117 Candida glabrata isolates

From: Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010–2018)

Methodology	Antifungal	No.	MIC⁵⁰	MIC⁹⁰	Susceptible	Resistant
			(µg/mL)	(µg/mL)	(%)	(%)	95% CI
CLSI	Caspofungin	117	0.06	0.12	90.6	9.4	4.8–16.2
Breakpoints	Micafungin	102	0.016	0.016	99.0	1.0	0.0–5.3
	Fluconazole	117	4	32	94.9	5.1	1.9–10.8

		No.	MIC⁵⁰	MIC⁹⁰	WT¹	NWT²	95% CI
			(µg/mL)	(µg/mL)	(%)	(%)
CLSI	Amphotericin B	117	0.5	0.5	100.0	0.0	0.0–3.1
ECV³	Itraconazole	60	0.25	0.5	98.3	1.7	0.0–8.9
	Posaconazole	63	0.25	1	93.7	6.3	1.8–15.5
	Voriconazole	116	0.06	0.25	92.2	7.8	3.6–14.2

¹Wild type
²Non-wild type
³Epidemiological cut-off value

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com